Dapagliflozin treatment in IgA nephropathy patients
- Conditions
- IgA nephropathy
- Registration Number
- JPRN-jRCT1031220369
- Lead Sponsor
- Tomohito Gohda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
(1) Diagnosis of IgA nephropathy by renal biopsy
(2) IgA nephropathy patients treated with dapagliflozin
(3) 20 years of age and older at the time of consent acquisition
(4) Receiving maximum tolerated dose of RAS inhibitors (excluding not tolerable case due to AE)
(5) After completion of predonine treatment
(6) eGFR more than 25 mL/min/1.73 m2
(7) Postive proteinuria
(8) Patients who have been fully informed about their participation in this study, and who have given their free and voluntary written consent based on a thorough understanding of the subject's own
(1) Patients who are taking or may start steroids or other immunosuppressive drugs during the study period
(2) Patients who cannot walk on their own and need assistance or a wheelchair to get to the hospital
(3) Patients under treatment for malignant tumors
(4) BMI less than 18
(5) Other exclusion criteria include patients deemed inappropriate as research subjects by the principal investigator
A research subject is eligible if he/she meets all of the selection criteria and none of the exclusion criteria listed above
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in proteinuria and eGFR from baseline
- Secondary Outcome Measures
Name Time Method